957313-52-9

Basic information

• Product Name: 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine
• Synonyms: 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine;5-(2-Methoxyphenyl)-2-Methylpyrazol-3-aMine;3-(2-methoxyphenyl)-1-methyl-1H-pyrazol-5-amine(WXC04717)
• CAS NO: 957313-52-9
• Molecular Formula: C11H13N3O
• Molecular Weight: 203.24
• Mol File: 957313-52-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 361.7°C at 760 mmHg
• Flash Point: 172.6°C
• Appearance: /
• Density: 1.19
• Vapor Pressure: 2.03E-05mmHg at 25°C
• Refractive Index: 1.6
• PKA: 3.71±0.10(Predicted)
• CAS DataBase Reference: 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine(957313-52-9)
• EPA Substance Registry System: 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine(957313-52-9)

Safety Data

• Hazardous Substances Data: 957313-52-9(Hazardous Substances Data)

Usage

General Description

3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine is a chemical compound with the molecular formula C11H13N3O. It is a pyrazole derivative with a substituted phenyl and methyl group, as well as a methoxy group attached to the phenyl ring. 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine has potential applications in medicinal chemistry, as it may exhibit biological activity and could be used as a building block for the synthesis of pharmaceutical drugs. It is important to handle this chemical with caution and to adhere to safety protocols, as exposure to it may pose health risks. Further research and testing are necessary to determine the specific properties and potential uses of 3-(2-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine.

InChI:InChI=1/C11H13N3O/c1-14-11(12)7-9(13-14)8-5-3-4-6-10(8)15-2/h3-7H,12H2,1-2H3

Relevant articles and documents

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.